Search research articles
Contact Us
Filters
Showing results (111-120 of 145) with videos related to
Page
of 15
Sort By:
Blood
|
July 15, 1993
Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements
F Lo Coco, P G Pelicci, F D'Adamo, et al.
The New England Journal of Medicine
|
May 17, 1990
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy
F Mandelli, G Avvisati, S Amadori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 1998
The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years
R Latagliata, G Avvisati, F Lo Coco, et al.
Haematologica
|
October 17, 2001
High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study
R Gastaldi, P Martino, G Gentile, et al.
Haematologica
|
March 1, 1993
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report
M A Aloe Spiriti, M C Petti, R Latagliata, et al.
Blood
|
April 15, 1991
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia
F Lo Coco, G Avvisati, D Diverio, et al.
British Journal of Haematology
|
July 1, 1990
High serum IL-2 levels are predictive of prolonged survival in multiple myeloma
G Cimino, G Avvisati, S Amadori, et al.
Leukemia & Lymphoma
|
January 1, 1993
Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?
M A Aloe Spiriti, M C Petti, R Latagliata, et al.
British Journal of Haematology
|
August 1, 1991
Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype
F Lo Coco, G Avvisati, D Diverio, et al.
Leukemia
|
April 1, 1993
Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia
A Spadea, M C Petti, P Fazi, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 145) with videos related to
Sort By:
Page
of 15
Blood
|
July 15, 1993
Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements
F Lo Coco, P G Pelicci, F D'Adamo, et al.
The New England Journal of Medicine
|
May 17, 1990
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy
F Mandelli, G Avvisati, S Amadori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 1998
The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years
R Latagliata, G Avvisati, F Lo Coco, et al.
Haematologica
|
October 17, 2001
High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study
R Gastaldi, P Martino, G Gentile, et al.
Haematologica
|
March 1, 1993
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report
M A Aloe Spiriti, M C Petti, R Latagliata, et al.
Blood
|
April 15, 1991
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia
F Lo Coco, G Avvisati, D Diverio, et al.
British Journal of Haematology
|
July 1, 1990
High serum IL-2 levels are predictive of prolonged survival in multiple myeloma
G Cimino, G Avvisati, S Amadori, et al.
Leukemia & Lymphoma
|
January 1, 1993
Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?
M A Aloe Spiriti, M C Petti, R Latagliata, et al.
British Journal of Haematology
|
August 1, 1991
Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype
F Lo Coco, G Avvisati, D Diverio, et al.
Leukemia
|
April 1, 1993
Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia
A Spadea, M C Petti, P Fazi, et al.
Page
of 15